儿科

订阅

MedSci主页 / 所有栏目 / 儿科

反应停受害者针对反应停基金会前理事会成员的诉讼胜诉

2017-06-08 佚名 不详

美通社
关注

反应停（沙利度胺）受害者安德列斯-梅耶(Andreas Meyer)（原告）和Contergan Foundation（反应停基金会）前理事会成员卡尔-舒赫特(Karl Schucht)律师（被告）之间的诉讼于2017年5月10日在波恩地区法院(Bonn Regional Court)作出判决。

反应停（沙利度胺）受害者安德列斯-梅耶(Andreas Meyer)（原告）和Contergan Foundation（反应停基金会）前理事会成员卡尔-舒赫特(Karl Schucht)律师（被告）之间的诉讼于2017年5月10日在波恩地区法院(Bonn Regional Court)作出判决。此判决并非最终判决。这个案件主要是调查格兰泰(Grunenthal)与Federal German Contergan Foundation（德国联邦反应停基金会）之间可能合作的问题。

柏林律师事务所Raue Rechtsanwalte LLP的让-赫格曼(Jan Hegemann)教授（博士）将一直都是梅耶的代理律师。

欲查看2017年6月8日的完整新闻稿，请访问：http://www.gruenenthalopfer.de/press_ContVict_wins_agains_memb_ContFound_8_6_2017。

通过以下链接：http://www.gruenenthal-opfer.de/Materials_Judgement_Meyer_vs_Schucht_10_05_2017可浏览判决内容及更多信息。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1667052, encodeId=ab77166e052f9, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Sun Oct 29 11:03:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458377, encodeId=b83e14583e76b, content=<a href='/topic/show?id=43e23e726b4' target=_blank style='color:#2F92EE;'>#反应停#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37726, encryptionId=43e23e726b4, topicName=反应停)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc576038485, createdName=hongbochen, createdTime=Sat Jun 10 01:03:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208136, encodeId=46a32081367f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jun 08 11:19:25 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-10-29 wjcjjian

    #诉讼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1667052, encodeId=ab77166e052f9, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Sun Oct 29 11:03:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458377, encodeId=b83e14583e76b, content=<a href='/topic/show?id=43e23e726b4' target=_blank style='color:#2F92EE;'>#反应停#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37726, encryptionId=43e23e726b4, topicName=反应停)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc576038485, createdName=hongbochen, createdTime=Sat Jun 10 01:03:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208136, encodeId=46a32081367f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jun 08 11:19:25 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-10 hongbochen

    #反应停#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1667052, encodeId=ab77166e052f9, content=<a href='/topic/show?id=1bbf915547d' target=_blank style='color:#2F92EE;'>#诉讼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91554, encryptionId=1bbf915547d, topicName=诉讼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef326082418, createdName=wjcjjian, createdTime=Sun Oct 29 11:03:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458377, encodeId=b83e14583e76b, content=<a href='/topic/show?id=43e23e726b4' target=_blank style='color:#2F92EE;'>#反应停#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37726, encryptionId=43e23e726b4, topicName=反应停)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc576038485, createdName=hongbochen, createdTime=Sat Jun 10 01:03:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208136, encodeId=46a32081367f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jun 08 11:19:25 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 1e17414fm02(暂无匿称)

    学习

    0

相关资讯

中国经导管人工瓣膜产品上市，开启介入心脏瓣膜治疗时代

全新呼吸诊疗随访一体化方案落地无锡

NLS Pharma称NLS-1治疗成人ADHD患者的二期数据令人鼓舞

知未来 创未来：英特尔为业务发展变革提供创新驱动力量

抗击脊灰 大爱无言 -- 赛诺菲心系邳州希望之家

Dymax戴马斯现推出极细针头粘接的1406-M医用胶粘剂